WG
STRO icon

Winton Group’s Sutro Biopharma STRO Stock Holding History

Winton Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,065
Closed -$198K – 1477
2021
Q2 		$198K Sell
1,065
-23
-2% -$4.5K 0.01% 1348
2021
Q1 		$248K Buy
+1,088
New +$258K 0.01% 1218
2020
Q4 		– Sell
-1,338
Closed -$134K – 1498
2020
Q3 		$134K Buy
+1,338
New +$126K ﹤0.01% 1379

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Winton Group's STRO Position: Q3 2021 in Review

Winton Group sold out of Sutro Biopharma (STRO) in Q3 2021, closing a stake of 1,065 shares — an estimated $198K sold.

Winton Group first reported a position in STRO in Q3 2020 and held it in 3 quarters. The position peaked at $248K in Q1 2021. 120 funds tracked by Wall St. Rank hold STRO as of Q3 2021.

  • Winton Group reported no remaining Sutro Biopharma position as of Q3 2021 after selling out during the quarter.
  • Winton Group sold 1,065 Sutro Biopharma shares in Q3 2021, an estimated $198K.
  • Winton Group first reported a position in Sutro Biopharma in Q3 2020 and held it in 3 quarters.
  • Winton Group's Sutro Biopharma position peaked at $248K in Q1 2021.
  • 120 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2021.

Based on Winton Group's 13F filing for Q3 2021, filed 28 Oct 2021.